Tofacitinib, taken orally and sold under the brand name Xeljanz among others, was tested in a trial of 289 patients hospitalized with severe Covid across 15 locations in Brazil.
After 28 days, 18.1 percent of the group receiving the tofacitinib progressed to respiratory failure or death, compared to 29 percent in the placebo group.Respiratory failure refers to a patient requiring noninvasive ventilation through an oxygen mask, or being intubated and placed on a mechanical ventilator.
Serious side effects occurred in 14.1 percent in the tofacitinib group and in 12 percent in the placebo group.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: